Close Menu
Home » Correction

Correction

Feb 04, 2005
Premium

RNAi News incorrectly reported last week that CytRx CEO Steven Kriegsman had stated than an investigational new drug application for an siRNA-based amyotrophic lateral sclerosis treatment is expected to be filed in the second half of 2005.

Although the company’s earlier goal of filing an IND before the end of 2004 was dropped, a new timeline has not been established.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Scan

To See More Clearly

Nature News reports that researchers in Japan hope to soon test the use of reprogrammed stem cells to treat damaged corneas.

Which Fish Is Which?

A new approach may help limit the number of fish that are mislabeled at markets or restaurants, according to New Scientist.

The Suspects, Too

At Slate, the R Street Institute's Nila Bala discusses the privacy rights of suspects that genetic genealogy approaches in law enforcement bring up.

This Week in PNAS

In PNAS this week: numerous mobile genetic elements contribute to Vibrio cholerae drug resistance, troponin I mutations in sudden infant deaths, and more.

Mar
21
Featured Webinar

A Long-Read vs. Short-Read Platform Comparison (Part 2): Best NGS Approaches for Human Transcriptome Sequencing

Sponsored by
Loop Genomics

This webinar provides a comparison of next-generation sequencing (NGS) approaches for human transcriptome sequencing, including short-read Illumina sequencing and synthetic long-read sequencing technology.

Apr
17
Featured Webinar

Biomarker Strategies for Optimizing Checkpoint Immunotherapy Treatment

Sponsored by
Isoplexis

This webinar will provide an overview of current biomarker strategies for guiding the use of combination checkpoint immunotherapies in blood cancers.

What's Popular?

In Gene Silencing/Gene Editing

  1. Broad Institute, Massachusetts General Hospital License CRISPR Tech to Pairwise

  2. NIH Expresses Support for Germline Editing Moratorium

  3. Mammoth Biosciences Licenses New CRISPR Enzyme for Disease Detection Applications

    Premium

Sponsorships

Privacy Policy.  Terms & Conditions.  Copyright © 2019 GenomeWeb LLC.  All Rights Reserved.